Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein-protein Interfaces02:04

Protein-protein Interfaces

12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Protein Networks02:26

Protein Networks

3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
2.7K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

296
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
296
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between height of cheer basket toss and specific physical ability of bases from a kinematic perspective.

Scientific reports·2025
Same author

Ultrathin organic solvent nanofiltration membrane with polydopamine-HKUST-1 interlayer for organic solvent separation.

Journal of environmental sciences (China)·2024
Same author

Response of sediment transport capacity to soil properties and hydraulic parameters in the typical agricultural regions of the Loess Plateau.

The Science of the total environment·2023
Same author

Dysregulated circular RNAs as novel biomarkers in esophageal squamous cell carcinoma: a meta-analysis.

Cancer medicine·2021
Same author

[The expression and significance of Notch1 in the human kidney tubular cell transdifferentiation induced by TGF-β(1);].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology·2011
Same author

Construction of microRNA- and microRNA*-mediated regulatory networks in plants.

RNA biology·2011

Related Experiment Video

Updated: May 23, 2025

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.6K

Multi-filter based signed heterogeneous graph convolutional networks for predicting activating/inhibiting drug-target

Ming Chen1, Haike Li1, Yunhan Pan1

  • 1College of Information Science and Engineering, Hunan Normal University, Changsha, 410081, China.

Methods (San Diego, Calif.)
|May 17, 2025
PubMed
Summary

This study introduces a novel graph convolutional network to predict drug-target interaction mechanisms, distinguishing between activation and inhibition. The model enhances drug discovery by analyzing drug-target interactions on signed networks.

Keywords:
Common targetsDrug-target interactionsGraph convolutional networkGraph signal processingSigned graphs

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

Related Experiment Videos

Last Updated: May 23, 2025

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

Area of Science:

  • Computational Biology
  • Drug Discovery
  • Network Science

Background:

  • Drug-target interactions (DTIs) are crucial for drug discovery but predicting their activating/inhibiting mechanisms remains challenging.
  • Traditional laboratory methods for DTI analysis are time-consuming and expensive.
  • Existing DTI prediction studies often overlook the specific mechanisms of activation or inhibition.

Purpose of the Study:

  • To develop a computational model for predicting the activating and inhibiting mechanisms of drug-target interactions.
  • To leverage signed heterogeneous networks to represent and analyze DTIs and drug-drug relationships.
  • To introduce a novel multi-filter based signed heterogeneous graph convolutional network (MFSHGCN) for enhanced DTI mechanism prediction.

Main Methods:

  • Modeling DTIs on signed heterogeneous networks, categorizing interactions into signed links.
  • Constructing signed drug-drug links based on drug coherence/incoherence on common targets.
  • Proposing a multi-filter based signed heterogeneous graph convolutional network (MFSHGCN) using dual filters for spectral information convergence from positive and negative edges.
  • Developing an end-to-end framework for predicting activation and inhibition in DTIs.

Main Results:

  • The MFSHGCN model effectively predicts drug-target interaction mechanisms, outperforming existing methods.
  • The incorporation of drug pair coherence/incoherence and the multi-filter system significantly improved prediction metrics.
  • The model demonstrates high prediction accuracy even without extensive node information or drug/target pair interactions.
  • Case studies on breast and lung cancer validated the model's practical feasibility and effectiveness.

Conclusions:

  • The proposed MFSHGCN framework offers a powerful computational approach for predicting drug-target interaction mechanisms.
  • This method can accelerate the drug discovery pipeline by providing mechanistic insights into DTIs.
  • The model's ability to work with limited node information makes it broadly applicable in bioinformatics and drug development.